Practical implication
Healthcare providers and laboratories must adhere to the recall notification and ensure the withdrawal of the affected lot of the QIAstat-Dx Gastrointestinal Panel 2.
The French National Agency for the Safety of Medicines and Health Products (ANSM) has issued safety information regarding the QIAstat-Dx Gastrointestinal Panel 2, including some significant actions linked to a product recall due to identified safety concerns.
What changed: ANSM announced a safety action with registration number R2626013 regarding a product recall for QIAstat-Dx Gastrointestinal Panel 2 (Recall No. R2624620), as of September 9, 2026.
Why it matters: This safety information is crucial for healthcare providers and laboratories utilizing the QIAstat-Dx Gastrointestinal Panel 2 to ensure patient safety and compliance with the recall process.
Practical implication: Healthcare providers and laboratories must adhere to the recall notification and ensure the withdrawal of the affected lot of the QIAstat-Dx Gastrointestinal Panel 2.
View original source
- Source: ANSM (France) - Safety information feed
- Published at source: 2026-09-09T00:00:00.000Z
- Discovered by monitor: 2026-09-09T21:45:29.780Z
Published from the regulator source ingestion pipeline after PV impact triage.
